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s warranted. Active infection control program in resource-limited
ettings for carbapenem resistant Gram-negative pathogens may
nclude modiﬁed active surveillance, contact isolation, cohorting
atients with carbapenem resistant Gram-negative pathogens, 5
oment hand hygiene, environmental cleaning, as well as moni-
oring healthcare workers and providing prompt feedback. These
trategies must be modiﬁed to ﬁt the local setting, organizational
ulture, and infrastructure. Intensiﬁed efforts in infection control
rograms and antibiotic stewardship serve as key components
or long-term success. Given the limited information of infec-
ion control for carbapenem resistant Gram-negative pathogens
n resource-limited setting, additional well-designed studies are
eeded to explore various aspects of outcomes of antimicrobial
tewardship and infection control in resource-limited settings.
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olio eradication – Incorporating IPV more broadly
. Vidor
Sanoﬁ Pasteur, Lyons, France
While the oral poliovirus vaccine (OPV) has been an important
ool in moving towards global eradication of poliomyelitis, its con-
inued use is associated with the ongoing emergence of circulating
accine-derived polioviruses (cVDPVs) and the sporadic occur-
ence of vaccine-associated paralytic poliomyelitis (VAPP) cases.
dditionally, sub-optimal andgeographically inconsistent serocon-
ersion rates following OPV administration further confound the
oal of global eradication.
The inactivated poliovirus vaccine (IPV), however, is not asso-
iated with cVDPVs or VAPP, and results in more consistent
ost-vaccination seroconversion rates. With these advantages in
ind, it is clear that IPV can play a vital role in global poliomyeli-
is eradication, but IPV is less straightforward to administer and is
laimed to be more expensive to deploy than OPV. Mixed and com-
ined OPV/IPV schedules can be used to maximize the beneﬁts of
oth vaccines.
TheWHOconsiders that IPVcouldhavean important role toplay
n low- to middle-income countries, where polio is particularly dif-
cult to eradicatedue to the continueduseofOPV. There arevarious
ossibilities, each with its own pros and cons and variable feasibil-
ty, to promote a broader incorporation of IPV in such countries,
ncluding; fractional doses administered intradermally; develop-
ent of new adjuvants for IPV antigens; an intramuscular schedule
ith a reduced number of doses; or the use of whole-cell pertussis
wP), rather than the more expensive acellular pertussis antigens,
n combination with IPV (eg, hexavalent wP-IPV-containing vac-
ines). In addition, the use of standalone IPV following previous
PV doses could also reduce the immunity gap that is present in
any pediatric populations.
The WHO currently envisages the cessation of wild-typeoliovirus circulation by 2014 through use of IPV, followed by con-
inued IPV use to assure and maintain global eradication.
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The evolution of pertussis vaccines and vaccination programs
U. Thisyakorn
Chulalongkorn University, Bangkok, Thailand
Pertussis, sometimes called whooping cough, is a highly conta-
gious disease that remains an important cause of death worldwide,
more particularly in developing countries. Its mortality occurs
largely in infants less than 1 year of age, especially among those
who have not completed their primary vaccinations.
Diphtheria and tetanus toxoids combinedwithwhole cellBorde-
tella pertussis (DTwP) vaccines were developed and licensed during
the 1940s, have been widely used for over 60 years, and have been
central to theWHOExpandedProgramon Immunization (EPI) since
its inception in 1974, leading to considerable impact in controlling
pertussis. However, there are still global disparities with regard to
vaccine use and coverage.
Concerns about the reactogenicity of DTwP vaccines led to
reduced immunization coverage and a subsequent increase in dis-
ease incidence in some countries. This prompted the development
of acellular (aP) pertussis vaccines, which have a considerably bet-
ter safety proﬁle.
Currently, DTaP vaccines – sometimes combined with other
antigens – are used in the national immunization programs
in Canada, the United States, various European countries (eg,
Denmark, France, Germany, Ireland, Italy, Spain, Sweden, UK),
Asia (eg, Japan, South Korea), Australia, Costa Rica, Mexico, South
Africa, and Turkey. National surveillance programs and speciﬁc
studies in Europe and North America have demonstrated that the
licensed aP vaccines, regardless of the number of acellular pertus-
sis components contained therein, have substantial effectiveness
in preventing pertussiswhen used comprehensively among infants
and young children.
Thebroaderdeploymentof aPvaccines andchildhoodcombined
vaccines is of considerable public health interest. Experience with
the use of these vaccines will be presented.
http://dx.doi.org/10.1016/j.ijid.2012.05.074
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Pentavalent and hexavalent combination vaccines of today and
tomorrow
S. Madhi
National Institute for Communicable Diseases (NICD), Johannesburg,
South AfricaVaccines are cost-effective public health tools for the preven-
tion and control of infectious diseases. However, disparity in access
to health care remains a major hurdle to accessing life-saving
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accines. The past decade has shown an increase in the num-
er of vaccines currently licensed and recommended for use in
nfants and children, and so the development of combined vaccines
as been a public health interest and priority. The advantages of
ew childhood combined vaccines are numerous. Combined vac-
ines – such as pentavalentDTaP–IPV//Hib or hexavalentDTaP-Hep
-IPV-Hib (diphtheria [D], tetanus [T], acellular pertussis [aP], hep-
titis B [Hep B], inactivated poliomyelitis [IPV], and conjugated
aemophilus inﬂuenzae type b [Hib] antigens) – lead to improved
ompliancewith the recommended infant immunization schedules
y providing needed protection while requiring fewer injections.
dditionally, shortages of important childhood vaccines (due to
roduction challenges at a particular manufacturing facility), asso-
iated reductions in vaccination coverage rates, and increased
ncidence of disease have been documented. The availability of
ultiple combination vaccines from different manufacturers can
elp prevent such shortages.
Several countries have implemented the use of aP and IPV anti-
ens, mainly as components of combination vaccines, with the aim
f reducing vaccine-associated adverse event rates while avoid-
ng vaccine-associated paralytic poliomyelitis and vaccine-derived
olioviruses. In addition, multiple studies demonstrate that the
icensed aP vaccines are effective in controlling pertussis. The use of
uch combination vaccines in routine practice continues to expand.
The clinical trial database of these vaccines is large, still growing,
nd provides reassurance concerning their high immunogenicity
nd excellent safety proﬁles. Contributing to this database aremul-
iple trials of a new fully-liquid hexavalent vaccine. This particular
ombination vaccine has been studied using different schedules,
ncluding at: 6, 10, 14weeks of age (theWHOExpandedProgramon
mmunization [EPI]-recommendedschedule); 2, 3, 4monthsof age;
nd 2, 4, 6 months of age. An overview of clinical data for several
ifferent combinationvaccineswill be included in thepresentation.
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pidemiology of typhoid fever
. Ochiai1,∗, M.I. Khan1, S. Sahastrabuddhe2, T. Wierzba2
International Vaccine Institute, Seoul, Korea, Republic of
International Vaccine Institute, Seoul, Others - Please Specify, Korea,
epublic of
Typhoid fever remains an important public health problem in
he world especially in the impoverished population from devel-
ping countries. Globally, the disease is estimated to cause 220,000
eaths and 22 million illnesses per year, predominantly in children
f school-age or younger. Typhoid fever is one of themost common
tiological sources of bacteraemia in many developing countries.
ithin the countries, the disease burden is often heterogeneously
istributed with the areas with poor hygiene and sanitation suffer-
ng the most.
Studies from urban slums in India and Bangladesh reported
ery high incidence rate of typhoid fever in young children. A ret-
ospective analysis of laboratory data from an urban hospital in
epal identiﬁed typhoid infection to be one of the most leading
auses of bacteraemia. Though these data are indication of highnfectious Diseases 16S (2012) e2–e157 e29
typhoid burden, utilizing different methods makes direct compar-
ison impossible.
The DOMI programme conducted a prospective, population-
based surveillance in ﬁve Asian countries – China, India, Indonesia,
Pakistan, and Vietnam – using standardized surveillance, clinical,
and microbiological methods to comparatively assess the burden
of typhoid fever in the region.
The incidence rate of typhoid fever ranged from 15.3 cases per
100,000 persons 5 to 60 years old in China to 451.7 cases per
100,000 persons 2 to 15 years old in Pakistan. In the 5 to 15 year old
age group, the incidence rate ranged from 24.2 cases per 100,000
persons in Vietnam to 493.5 cases per 100,000 persons in India.
For sites where surveillance was additionally undertaken in pre-
school children (2 to 5 years of age), the incidence rate was found
to be comparable to older children. Multidrug resistance (resistant
to chloramphenicol, ampicillin and TMP-SMX) was observed from
85/127 S. Typhi isolates from Pakistan, 4/18 from Vietnam, and
8/113 from India.
The ﬁnding highlights the considerable, but geographically het-
erogeneous, burden of typhoid fever in endemic areas of Asia, and
underscores the importance of evidence on disease burden inmak-
ing policy decisions about interventions to control this disease.
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Solving the typhoid diagnostics conundrum
S. Baker
Oxford University Clinical Research Unit - Hospital for Tropical Dis-
eases, Ho Chi Minh, Viet Nam
Typhoid fever is serious bacterial infection caused by the bac-
terium Salmonella Typhi and other related invasive Salmonella.
In endemic areas, diagnostic tests are needed to diagnose acute
cases for clinical management, to detect convalescent and chronic
fecal carriage and for contact tracing. However, the diagnostic tests
that are currently used are poor. Blood culture is the currently
mainstay of typhoid diagnostics, yet is insufﬁciently sensitive and
technically demanding, and bone marrow culture, although more
sensitive, is infrequently performed. There is a clear need for a
novel approach to typhoid diagnostics. We have made extensive
inroads into understanding how the organisms are transmitted and
how they interact with the human host. Yet, these new insights
into studying disease have not, as yet, let to new approaches for
diagnosing typhoid fever.
As the result of ameetingheld in London in2010,wehavegener-
ated a typhoid fever diagnostics working group. Though a number
of collaborations, generated through this group, we have investi-
gated a number of novel techniques aimed at developing the next
diagnostic test for typhoid.
Here, I discuss the approach of the typhoid diagnostics consor-
tium and I present the preliminary data for several methods which
may become the gold standard for typhoid diagnosis in the future.
We have a clear blueprint for the next typhoid diagnostic and
through the typhoid community we hope to develop some of the
these new tests over the coming years, taking the leading method
into production
http://dx.doi.org/10.1016/j.ijid.2012.05.077
